Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy
A study is underway to evaluate divarasib's efficacy against standard immunotherapy options in NSCLC patients.
| Drug | MOA / Company | Stage |
|---|---|---|
| Divarasib | Roche | Lead |
| Pembrolizumab | — | Competing |
| Nivolumab | — | Competing |
Focal Asset
Divarasib
Company
Roche
Indication
Oncology / KRAS G12C-Positive Non-Small Cell Lung Cancer
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing trial of divarasib against established immunotherapies could significantly alter treatment protocols for KRAS G12C-positive NSCLC. A successful outcome may enhance Hoffmann-La Roche's market position and influence competitive dynamics in oncology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any updates on patient outcomes and safety profiles.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.